Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults

Amy Y. Wang, MD, MPH; Lori S. Muffly, MD, MS; Wendy Stock, MD

Disclosures

J Oncol Pract. 2020;16(5):231-238. 

In This Article

New Front-line Approaches to Eradicate MRD

The next frontier in the effort to eradicate MRD is the incorporation of targeted therapies into existing front-line regimens. In the United States, the adult National Clinical Trials Network has recently opened Alliance Trial 041501 (AO41501; ClinicalTrials.gov identifier: NCT03150693), the successor trial to CALGB 10403, which is investigating the incorporation of inotuzumab ozogamicin (IO), an anti-CD22 antibody conjugated to calicheamicin, into the front-line setting.[34] Similarly, the National Cancer Institute–sponsored ECOG-E1910 trial (ClinicalTrials.gov identifier: NCT02003222) is investigating the combination of blinatumomab with a front-line chemotherapy regimen. For AYAs with Ph-like ALL, another approach undergoing investigation is the addition of a targeted kinase inhibitor because of the high number of CRLF2 and JAK fusions.[35] One such clinical trial is combining ruxolitinib, a JAK2 inhibitor, with front-line chemotherapy in AYAs with Ph-like ALL (ClinicalTrials.gov identifier: NCT03571321).

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....